Site icon OncologyTube

FAST Phase 2 Trial: IMAB362 for Gastric, GEJ, and Esophageal Cancers

Steven E. Benner, MD, Senior Vice President and Global Therapeutic Head for Oncology at Astellas Oncology gives an overview of the results of the FAST Phase 2 Trial, which was presented by Martin H. Schuler, MD at the 2017 ASCO Annual Meeting in Chicago, IL.

Abstract 4028: Expression of Claudin 18.2 and HER2 in gastric, gastroesophageal junction (GEJ), and esophageal cancers: Results from the FAST Study

Advertisement
Exit mobile version